Analytical Issues Surrounding Troponin Assays
Shades of Gray
October 2010
The diagnostic challenge relies on clearly differentiating patients who do have had an acute myocardial infarction from those who have not and can be sent home. Furthermore, situations are often not black and white and decisions are often needed about what to do with those patients with slightly elevated troponins but aren’t changing (i.e., in the gray zone).
Shades of Gray |
Jump to section:
- Introduction
- Challenges in Cardiovascular Medicine
- Shades of Gray
- Cardiac Markers
- Troponin Elevations are Greater and Persist Over Longer Time Periods
- 2007 Universal Definition of MI1
- Serial Sampling
- Elevation of cTn in Patients Without Overt Ischemic Heart Disease1
- Analytic Confusion: Sensitivity and Imprecision of cTn Assays
- Analytical Definitions (Related to Troponin)
- Current Troponin Assays
- Defining the 99th Percentile (Normal Population)
- Troponin T or Troponin I: Does it Matter?
- Is CK-MB Needed Anymore?
- Recommendations for Point-of-Care Cardiac Marker Testing2,3
- Does POCT Make Any Difference?
- What About the High-Sensitive Troponin Assays?
- Why All the Hype for High-Sensitivity Troponin?
- Troponin Concentrations and Diagnostic Accuracy4
- How Sensitive Does Troponin Testing Really Need to Be?
- Current Mayo Cardiac Biomarker Panel
- Current Mayo Cardiac Biomarker Panel
- Conclusions
- References
- Questions?
- Disclosure
External
link
PDF
document
Excel
document
Word
document